Across TCGA pan-cancer cohorts, TMX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMX2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMX2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMX2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where TMX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.593	1.000	<.001	61	view →
PDAC	OS	Median	II,III,IV	0.627	0.374	.009	19	view →
UCEC	DFS	Median	All	0.780	0.949	.009	4	view →
GBM	DFS	Median	All	0.458	0.298	.022	4	view →
LUAD	OS	Quartile	All	1.000	0.700	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TMX2 tumor-vs-normal RNA expression · all TMX2 data types